To evaluate pharmacokinetics and safety of AD-208.
The purpose is that pharmacokinetics and safety of AD-208 in healthy adult male volunteers are evaluated as compared to Avodart Soft Capsule 0.5mg.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Dutasteride 0.2mg
Dutasteride 0.5mg
Kyungpook National University Hospital
Daegu, South Korea
Area under the curve in time plot (AUCt)
AUCt of the total ingredient of dutasteride
Time frame: Pre-dose(0 hour) to 72 hour
Peak Plasma Concentration (Cmax)
Cmax of the total ingredient of dutasteride
Time frame: Pre-dose(0 hour) to 72 hour
Area under the curve in time plot (AUCinf)
AUCinf of the total ingredient of dutasteride
Time frame: Pre-dose(0 hour) to 72 hour
Time to reach Cmax(Tmax)
Tmax of the total ingredient of dutasteride
Time frame: Pre-dose(0 hour) to 72 hour
Effective half-life(t1/2)
t1/2 of the total ingredient of dutasteride
Time frame: Pre-dose(0 hour) to 72 hour
Clearance(CL/F)
CL/F of the total ingredient of dutasteride
Time frame: Pre-dose(0 hour) to 72 hour
Volume of distribution(Vd/F)
Vd/F of the total ingredient of dutasteride
Time frame: Pre-dose(0 hour) to 72 hour
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.